SBI1997
Hepatocellular Carcinoma (HCC) - Prevention of Recurrence
PreclinicalActive
Key Facts
Indication
Hepatocellular Carcinoma (HCC) - Prevention of Recurrence
Phase
Preclinical
Status
Active
Company
About Saronic Biotechnology
Saronic Biotechnology is a private, preclinical-stage biotech company targeting hepatocellular carcinoma (HCC) with novel immunotherapies. Its lead candidate, SBI1997, is a cellular immunotherapy designed to prime the immune system to prevent cancer recurrence. Founded in 2021, the company is led by a team with deep expertise in liver disease and oncology, operating in the high-need but competitive cell and gene therapy sector for solid tumors.
View full company profile